MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Akcijų sąrašas・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Uždarymo kaina

1.3 5.69

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.21

Max

1.33

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-809K -5.9M
Pelno marža	-6,600
Darbuotojai	25
EBITDA	-1.3M -6.2M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+380% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	3.9M 35M
Ankstesnė atidarymo kaina	-4.39
Ankstesnė uždarymo kaina	1.3

Actinium Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-16 23:26; UTC

Karštos akcijos

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

2026-04-16 20:41; UTC

Pagrindinės rinkos jėgos

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

2026-04-16 23:49; UTC

Rinkos pokalbiai

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

2026-04-16 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline After Hitting Record High -- Market Talk

2026-04-16 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

2026-04-16 22:51; UTC

Rinkos pokalbiai

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

2026-04-16 22:08; UTC

Uždarbis

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Pre-Announces Items Impacting 1Q Results

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

2026-04-16 20:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-04-16 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-04-16 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-16 20:50; UTC

Rinkos pokalbiai

Uždarbis

Health Care Roundup: Market Talk

2026-04-16 20:49; UTC

Uždarbis

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

2026-04-16 20:43; UTC

Uždarbis

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

2026-04-16 20:40; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-04-16 20:40; UTC

Rinkos pokalbiai

Uždarbis

Netflix Says Engagement Quality Hits New High -- Market Talk

2026-04-16 20:30; UTC

Karštos akcijos

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

2026-04-16 20:25; UTC

Uždarbis

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

2026-04-16 20:23; UTC

Uždarbis

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

2026-04-16 20:19; UTC

Uždarbis

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

2026-04-16 20:17; UTC

Uždarbis

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

2026-04-16 20:17; UTC

Uždarbis

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Akcijų palyginimas

Kainos pokytis

Actinium Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

380% į viršų

12 mėnesių prognozė

Vidutinis 6 USD 380%

Aukščiausias 9 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Actinium Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Actinium Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.